Carnival Corp vs Smith & Nephew plc — how do they compare? Carnival Corp trades at $26.57 (market cap $36.30B), while Smith & Nephew plc trades at $30.06 (market cap $12.40B). The key difference: Carnival Corp is far larger — about 2.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.62%). Which is the better fit depends on your goals.
| CCL | SNN | |
|---|---|---|
Market Cap | $36.30B | $12.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.99 | $38.70 |
52-Week Low | $23.89 | $28.73 |
Enterprise Value | $60.22B | $15.17B |
Dividend Yield | 1.7% | 2.62% |
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $26.61, down 0.82% on the day, amid a bearish technical signal. The company demonstrates strong fundamental improvement with revenue growth to $26.62 billion in 2025 and net income of $2.76 billion, supported by three consecutive quarterly EPS beats. Positive analyst sentiment is evident with a $35.00 consensus price target and 59.57% buy ratings, while recent news highlights fleet expansion and strong bookings.
The outlook remains positive due to robust demand and cost controls, but risks include geopolitical tensions impacting fuel costs and softer European demand. The stock's current valuation metrics, such as a P/E of 11.99, suggest potential upside if execution continues, though investors must weigh debt levels and macroeconomic headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →